All In Biotech

Drug Trial Radar · NCT07764978

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (DURGA-5)

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

750

Planned (sponsor's estimate)

Start

Jun 26, 2026

Primary completion

Jan 11, 2029

Study completion May 12, 2034

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.

Conditions

  • Newly Diagnosed Multiple Myeloma

Interventions

  • AZD0120Biological

    AZD0120, is a BCMA/CD19 dual CAR T-cell product, which is administered intravenously.

  • DaratumumabBiological

    Induction, optional bridging and continuous therapy.

  • DexamethasoneDrug

    Induction, optional bridging and continuous therapy.

  • IsatuximabBiological

    Induction, optional bridging and continuous therapy.

  • LenalidomideDrug

    Induction, optional bridging and continuous therapy.

  • BortezomibDrug

    Induction therapy.

  • CyclophosphamideDrug

    Lymphodepletion

  • FludarabineDrug

    Lymphodepletion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction followed by AZD0120 compared to IsaVRd or DRd induction followed by continuous DRd or IsaRd.Time frame: Up to 9 years.
  2. MRD negative CR rate at 9M in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction followed by AZD0120 compared to IsaVRd or DRd induction followed by continuous DRd or IsaRdTime frame: Up to 9 years.

Locations

124 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Gilbert, Arizona · Not yet recruiting

  • Research Site

    Phoenix, Arizona · Not yet recruiting

  • Research Site

    Tucson, Arizona · Not yet recruiting

  • Research Site

    Orange, California · Not yet recruiting

  • Research Site

    Santa Monica, California · Not yet recruiting

  • Research Site

    Aurora, Colorado · Not yet recruiting

  • Research Site

    Denver, Colorado · Not yet recruiting

  • Research Site

    New Haven, Connecticut · Not yet recruiting

  • Research Site

    Coral Gables, Florida · Not yet recruiting

  • Research Site

    Tampa, Florida · Not yet recruiting

  • Research Site

    Atlanta, Georgia · Not yet recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Iowa City, Iowa · Not yet recruiting

  • Research Site

    Wichita, Kansas · Not yet recruiting

  • Research Site

    Louisville, Kentucky · Not yet recruiting

  • Research Site

    Baton Rouge, Louisiana · Not yet recruiting

  • Research Site

    Baltimore, Maryland · Not yet recruiting

  • Research Site

    Detroit, Michigan · Not yet recruiting

  • Research Site

    St Louis, Missouri · Not yet recruiting

  • Research Site

    East Brunswick, New Jersey · Not yet recruiting

  • Research Site

    Albany, New York · Not yet recruiting

  • Research Site

    New Hyde Park, New York · Not yet recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    The Bronx, New York · Not yet recruiting

  • Research Site

    Chapel Hill, North Carolina · Not yet recruiting

  • Research Site

    Charlotte, North Carolina · Not yet recruiting

  • Research Site

    Durham, North Carolina · Not yet recruiting

  • Research Site

    Winston-Salem, North Carolina · Not yet recruiting

  • Research Site

    Winston-Salem, North Carolina · Not yet recruiting

  • Research Site

    Cincinnati, Ohio · Not yet recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Columbus, Ohio · Not yet recruiting

  • Research Site

    Montgomery, Ohio · Not yet recruiting

  • Research Site

    Portland, Oregon · Not yet recruiting

  • Research Site

    Nashville, Tennessee · Not yet recruiting

  • Research Site

    Nashville, Tennessee · Not yet recruiting

  • Research Site

    Dallas, Texas · Not yet recruiting

  • Research Site

    Houston, Texas · Not yet recruiting

Showing 40 of 124 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.